Novo Nordisk Advances Next-Gen Obesity Strategy: Partners on Semaglutide Implant and Withdraws CagriSema Device Trial
Novo Nordisk A/S (NYSE: NVO) is actively reshaping its next-generation metabolic pipeline to pivot toward ultra long-acting delivery systems and optimized patient experiences. On July 7, 2026, the company made two major moves: establishing an agreement to evaluate a miniature, once- or twice-yearly semaglutide implant1, and withdrawing a specific device comparability study for its CagriSema combination therapy.
Ultra Long-Acting Semaglutide Implant Partnership with Vivani Medical
Seeking to address the chronic challenge of long-term medication non-adherence—which historically affects approximately 50% of patients taking daily or weekly therapies—Novo Nordisk signed a non-exclusive development agreement with Vivani Medical, Inc. (NASDAQ: VANI).
- The Technology: Novo Nordisk will conduct an internal evaluation of NPM-139, Vivani's miniature, ultra long-acting semaglutide implant that leverages its proprietary NanoPortal™ platform.
- Clinical Utility: The implant is designed for subdermal insertion, providing continuous, steady release of semaglutide over a 6-month to 12-month period. This once- or twice-yearly dosing profile could completely eliminate weekly injection burdens and guarantee therapeutic adherence2, while retaining the clinical option of being removed/stopped at any time.
- First-in-Human Progress: Separately from the Novo Nordisk evaluation, Vivani is initiating its own Phase 1, randomized, first-in-human study of NPM-139 in mid-2026, using Wegovy® injections as an active comparator.
Withdrawal of CagriSema Device Comparability Study
Concurrently, on July 7, 2026, Novo Nordisk updated its clinical trial registry to show the withdrawal of a placebo-controlled device comparability trial for CagriSema (the combination of amylin-analog cagrilintide and semaglutide).
- The Trial Scope: The study, titled "A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or Obesity," was designed to compare weight loss, ease of use, and tolerability between two different injectable device types delivering CagriSema.
- Strategic Meaning: While the withdrawal of this device-specific trial slightly clouds the near-term device rollout timeline, it does not signify a delay or cancellation of the core CagriSema drug development program. The core Phase 3 trials continue, and a regulatory decision from the FDA remains anticipated for late 2026. This withdrawal simply represents a design adjustment or streamlining of the device presentations as Novo Nordisk focuses its clinical development resources.
-
An instance of Weekly metabolic injections must yield to monthly and long-acting clinical alternatives. — Long-acting subdermal implants that deliver semaglutide for up to a year are being pioneered to bypass the weekly injection routine entirely and guarantee compliance. ↩︎
-
An instance of Daily weight-loss pills cannot defend their market share against the extreme convenience of monthly injections. — Novo Nordisk is actively developing ultra long-acting semaglutide implants to bypass the adherence challenges inherent to weekly and daily dosing schedules. ↩︎